1-6 of 6
Catherine Thieblemont
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5071: Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial

David Soong, Işıl Altıntaş, John Karavitis, Kim M. Linton, Wojciech Jurczak, Catherine Thieblemont, Kevin Zhao, Edith Szafer-Glusman, Daniela Hoehn, Elena Favaro, Mariana Sacchi, Maria Jure-Kunkel
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5071.
https://doi.org/10.1158/1538-7445.AM2024-5071
Published: 22 March 2024
View article titled, Abstract 5071: Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial
Journal Articles

Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas

M. Nieves Calvo-Vidal, Nahuel Zamponi, Jan Krumsiek, Max A. Stockslager, Maria V. Revuelta, Jude M. Phillip, Rossella Marullo, Ekaterina Tikhonova, Nikita Kotlov, Jayeshkumar Patel, Shao Ning Yang, Lucy Yang, Tony Taldone, Catherine Thieblemont, John P. Leonard, Peter Martin, Giorgio Inghirami, Gabriela Chiosis, Scott R. Manalis, Leandro Cerchietti
Journal: Cancer Research
Cancer Res (2021) 81 (20): 5202–5216.
https://doi.org/10.1158/0008-5472.CAN-21-2734
Published: 15 October 2021
View article titled, Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
Open the PDF for Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas in another window
Includes: Supplementary data
Journal Articles

Abstract 5616: Rituximab chemotherapy induces a partial recovery from T-cell exhaustion in follicular lymphoma patients

Benoit Milcent, Pauline Brice, Catherine Thieblemont, Jean-Luc Teillaud, Sophie Siberil
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5616.
https://doi.org/10.1158/1538-7445.AM2018-5616
Published: 01 July 2018
View article titled, Abstract 5616: Rituximab chemotherapy induces a partial recovery from T-cell exhaustion in follicular lymphoma patients
Journal Articles

Discovery of Human-Similar Gene Fusions in Canine Cancers

Ronan Ulvé, Mélanie Rault, Mathieu Bahin, Laetitia Lagoutte, Jérôme Abadie, Clotilde De Brito, Jean-Michel Coindre, Nadine Botherel, Audrey Rousseau, Valentin Wucher, Edouard Cadieu, Catherine Thieblemont, Christophe Hitte, Laurence Cornevin, Florian Cabillic, Laura Bachelot, David Gilot, Benoit Hennuy, Thierry Guillaudeux, Arnaud Le Goff, Thomas Derrien, Benoît Hédan, Catherine André
Journal: Cancer Research
Cancer Res (2017) 77 (21): 5721–5727.
https://doi.org/10.1158/0008-5472.CAN-16-2691
Published: 31 October 2017
View article titled, Discovery of Human-Similar Gene Fusions in Canine Cancers
Open the PDF for Discovery of Human-Similar Gene Fusions in Canine Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract CT132: A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB & Non-GCB subtypes

Marie Maerevoet, Jason Westin, Catherine Thieblemont, Josee Zijlstra, Brian T. Hill, Fatima De La Cruz Vicente, Sylvain Choquet, Paolo Caimi, Jason Kaplan, Miguel Albendea Canales, John Kuruvilla, George Follows, Eric Van den Neste, Julie Meade, Brendan Wrigley, Marissa Devlin, Conny Nippgen, Humphrey Gardner, Sharon Shacham, Michael G. Kauffman, Rene-Olivier Casasnovas
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT132.
https://doi.org/10.1158/1538-7445.AM2017-CT132
Published: 01 July 2017
View article titled, Abstract CT132: A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB & Non-GCB subtypes
Journal Articles

Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies

Patrice E. Herait, Celine Berthon, Catherine Thieblemont, Emmanuel Raffoux, Valeria Magarotto, Anastasios Stathis, Xavier Thomas, Xavier Leleu, Carlos Gomez-Roca, Elodie Odore, Christophe Roumier, Fabrice Bourdel, Bruno Quesnel, Emanuele Zucca, Mauricette Michallet, Christian Recher, Esteban Cvitkovic, Keyvan Rezai, Claude Preudhomme, Thierry Facon, Antonio Palumbo, Herve Dombret
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT231.
https://doi.org/10.1158/1538-7445.AM2014-CT231
Published: 01 October 2014
View article titled, Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies